Progenics Pharmaceuticals Inc. (PGNX): Price and Financial Metrics

Progenics Pharmaceuticals Inc. (PGNX)

Today's Latest Price: $4.36 USD

0.07 (1.63%)

Updated May 28 8:00pm

Add PGNX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

PGNX Stock Summary

  • With a price/sales ratio of 10.05, Progenics Pharmaceuticals Inc has a higher such ratio than 88.48% of stocks in our set.
  • With a year-over-year growth in debt of -10.16%, Progenics Pharmaceuticals Inc's debt growth rate surpasses only 20.45% of about US stocks.
  • Revenue growth over the past 12 months for Progenics Pharmaceuticals Inc comes in at 121.09%, a number that bests 95.4% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Progenics Pharmaceuticals Inc are MOSY, UTSI, ATNX, OIIM, and AWRE.
  • PGNX's SEC filings can be seen here. And to visit Progenics Pharmaceuticals Inc's official web site, go to
PGNX Daily Price Range
PGNX 52-Week Price Range

PGNX Stock Price Chart More Charts

PGNX Price/Volume Stats

Current price $4.36 52-week high $6.37
Prev. close $4.29 52-week low $1.89
Day low $4.24 Volume 684,100
Day high $4.51 Avg. volume 860,483
50-day MA $3.66 Dividend yield N/A
200-day MA $4.59 Market Cap 377.56M

Progenics Pharmaceuticals Inc. (PGNX) Company Bio

Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York.

PGNX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

PGNX Latest Social Stream

Loading social stream, please wait...

View Full PGNX Social Stream

Latest PGNX News From Around the Web

Below are the latest news stories about Progenics Pharmaceuticals Inc that investors may wish to consider to help them evaluate PGNX as an investment opportunity.

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.

Yahoo | May 18, 2020

Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The Firm

Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) in connection with the proposed merger between Progenics and Lantheus Holdings, Inc. The lawsuit seeks damages and/or equitable relief on behalf of Progenics shareholders under the federal securities laws.

Yahoo | May 8, 2020

Edited Transcript of PGNX earnings conference call or presentation 7-May-20 12:30pm GMT

Q1 2020 Progenics Pharmaceuticals Inc Earnings Call

Yahoo | May 8, 2020

Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and…

GlobeNewswire | May 7, 2020

Velan Capital Agrees to Support Merger of Lantheus and Progenics

NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has enter

Business Wire | April 14, 2020

Read More 'PGNX' Stories Here

PGNX Price Returns

1-mo 10.10%
3-mo -7.63%
6-mo -16.48%
1-year 0.93%
3-year -33.64%
5-year -22.56%
YTD -14.34%
2019 21.19%
2018 -29.41%
2017 -31.13%
2016 40.95%
2015 -18.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8854 seconds.